# Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application.

## Abstract
Compounds of formula I

## Claims
CLAIMS 1. A compound of formula I EMI100.1 and salts and in vivo hydrolysable acyl derivatives thereof, wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 is phenyl unsubstituted or substituted with one or two of the following fluorine, chlorine, bromine, trifluoromethyl, C16 straight or branched chain alkyl or C 1 6 straight or branched chain alkoxy or is benzofuran 2 yl R5 is a hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy A R is moiety EMI100.2 or O X1 CN wherein X is C2 10 alkylene which may be straight or branched provided that the oxygen and nitrogen are separated bv at least two carbon atoms, X is C1 9 alkylene which may be straight or branched, A is hydrogen C 1 6 straight or branched alkyl or benzyl optionally substituted with halogen, lower alkyl or lower alkoxy. R6 is hydrogen C16 straight or branched alkyl C16 straight or branched alkylslphonyl or EMI101.1 R7 is C1 6 straight or branched alkyl C16 straight or branched alkoxy amino, mono or di C1 6 straight or branched alkyl amino orEMI101.2 is cyclic amino optionally containing a second heteroatom selected from oxygen, nitrogen and sulphur and n is 1 or 2. 2. A compound as claimed in claim 1 wherein the carbon atom bearing the hydroxyl group and R3 has the R absolute configuration. 3. A compound as claimed in claim 1 and selected from F2 4 2 ethylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Dimethylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoro methylphenyl ethanamine N 2 4 2 Methylsulphonylaminoethoxy phenyl l methylethyll 2 hydroxy 2 3 trif luoromethylphenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethy 2 hydroxy 2 2 benzofuranyl ethanamine N 2 3 Fluoro 4 2 methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 ethylphenyl ethanamine N 2 4 2 Methylamino ethoxy phenyl l methylethyl 2 hydroxy 2 2 fluorophenyl ethanamine N L2 4 2 Methylaminoethoxy phenyl l methylethyl 3 2 hydroxy 2 3 bromophenyl ethanamine N C2 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 fluorophenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 phenylethanamine N 2 4 2 ethylar .in6ethoxy phenyl I rnethylethylj 2 hydroxy 2 2 fluoro 3 chlorophenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethyll2 hydroxy 2 4 chlorophenyl ethanamine N 2 4 2 Benzylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine N 2 4 2 1 Piperidine ethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine N 2 4 2 1 Homopiperidine ethoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethyl phenyl ethanamine N Ethoxycarbonylaminoethoxy phenyl l methylethy11 2 hydroxy 2 3 chlorophenyl ethanamine N 02 4 2 Methylaminocarbonylaminoethoxy phenyl 1 methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Benzylaminoethoxy phenyl l methylethylg 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Aminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Ethoxycarbonylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Acetylaminoethoxy phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine N 02 4 2 Methylaminoethoxy phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine, N C2 4 2 Methylaminoethoxy phenyl 1 methylethylj 2 hydroxy 2 3 triEluoromethylphenyl ethanamine RR,SS diastereoisomer N 2 4 2 1 Pyrrolidine ethoxy phenyl l methylethylJ 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 1 Piperidine ethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethyl phenyl ethanamine N 2 4 t2 Ethylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine RR,SS diastereoisomer N 12 3 2 Methylaminoethoxy phenyl l methylethyl5 2 hydroxy 2 3 chlorophenylethanaminc N 2 t4 2 1 Morpholinoiethoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Benzylaminopropoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Aminopropoxy phenyl l methylethylj 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 6 Methylaminohexyloxy phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 2 Aminoethoxy phenyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanaminei N 3 4 2 Dimethylaminoethoxy phenyl 1, l dimethyl propyl 2 hydroxy 2 phenylethanamine N 2 4 2 Dimethylaminoethoxy phenyl l methylethyl1 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 Cyanomethoxy phenyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine N 2 4 Cyanomethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine and salts thereof, 4. A process for producing a compound of formula I as defined in claim 1 or a salt thereof, which process comprises a reducing an oxo group and or a double bond and or a moiety reducible to a group R4 of a compound of formula it EMI104.1 wherein R1, R3, R5 and n are as defined in relation to formula I R11 is R4 or a moiety reducible to a group R4 as defined in relation to formula I R12 is a group R2 as defined in relation to formula I or together with R13 forms a bond R13 is hydrogen or benzyl or together with R12 or R14 forms a bond R14 is hydrogen or together with R15 forms an oxo group or together with R13 forms a bond R15 is hydrogen or together with R14 forms an oxo group R16 is hydroxyl or together with.R17 forms an oxo group R17 is hydrogen or together with R16 forms an oxo group, provided that there is no more than one oxo group and no more than one bond represented by any of R12 to R17, and optionally thereafter forming a salt of the compound of formula I so formed and or converting the compound of formula I so formed into a further compound of formula I , or b reacting a compound of formula III EMI105.1 or a compound of formula VIVID EMI105.2 with a compound of formula IV EMI105.3 wherein R1 R , R , R4 R5 and n are as defined in relation to formula I , and optionally thereafter forming a salt of the compound of formula I so formed or c reacting an alkali metal salt of a compoundEMI105.4 with a compound of formula VI EMI106.1 R1 R2 R3 R5 and n are R6 wherein I I I R5 R6 A X and n are as defined in relation to formula I , and Y is a leaving group. 5. A process as claimed in claim 4 a wherein the reduction is effected using hydrogen and palladium catalyst in a suitable solvent. 6. A process as claimed in claim 4 a wherein the reduction is effected using sodium borohydride in a suitable solvent. 7. A pharmaceutical formulation comprising a compound of formula I as defined in claim 1 and a pharmaceutically acceptable carrier therefor. 8. A pharmaceutical formulation as claimed in claim 8 in unit dosage form. 9. A process for producing a formulation as claimed in claim 7 which comprises bringing into association the compound of formula I and the carrier. 10. A compound as claimed in claim 1 for use in treating the human or animal body.

## Description
SECONDARY AMINES The present invention relates to derivatives of ethanolamine which have anti obesity and or anti hvperglycaemic and or anti inflammatory and or platelet aggregatio inhibition activity, to processes for their production and to their use in medicine. European Patent Application No. 79301197.4 Beechams discloses compounds of formulaEMI1.1 wherein R is hydrogen, fluorine, chlorine, hydroxyl, hydroxymethyl, methyl, methoxy, amino, formamido, acetamido, methylsulphonamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p methoxybenzylamino1 R2 is hydrogen, fluorine, chlorine or hydroxyl R3 is hydrogen, fluorine, chlorine or hydroxyl R4 is a carboxylic acid group or a salt, ester or amide thereof R5 is hydrogen, fluorine, chlorine, methyl, methoxy, hydroxyl, or a carboxylic acid group or a salt, ester or amide thereof R6 is hydrogen, methyl, ethyl or propyl R7 is hydrogen, methyl, ethyl or propyl X is oxygen or a bond and Y is C16 alkylene or a bond, which possess anti obesity and or hypoglycaemic activity. It has now been discovered that a class of novel phenoxyalkylaminoethanolamine derivatives have anti obesity and orthYneralycaemicand or anti inflammatory and or platelet aggregation inhibition activity. This activity is coupled with low cardiac stimulant activity for particular members of the class. Accordingly, the present invention provides a compound of formula I EMI2.1 and salts and in vivo hydrolysable acyl derivatives thereof, wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 is phenyl unsubstituted or substituted with one or two of the following fluorine, chlorine, bromine, trifluoromethyl, C16 straight or branched chain alkyl or C16 straight or branched chain alkoxy or is benzofuran 2 yl R5 is a hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy R4 is moietyEMI2.2 wherein X is CZ 10 alkylene which may be straight or branched provided that the oxygen and nitrogen are separated by at least two carbon atoms XÃš is C19 alkylene which may be straight or branched, A is hydrogen C16 straight or branched alkyl or benzyl optionally substituted with halogen, lower alkyl or lower alkoxy. R is hydrogen C1 6 straight or branched alkyl C16 straight or branched alkylsulphonylEMI3.1 R7 is C16 straight or branched alkyl C1 6 straight or branched alkoxy amino, mono or di C1 6 straight orbranched alkyl amino orEMI3.2 is a 5,6 or 7 membered cyclic amine optionally containing a second hetero atom selected from oxygen, nitrogen and sulphur, and n is 1 or 2Suitable cyclic aminesEMI3.3 include pyrrolidine, piperidine, homopiperidine and morpholine groups. Pharmaceutically acceptable salts of compounds of formula I include acid addition salts formed with a pharmaceutically acceptable acid such as hydrochloric acid, hydrobromic acid, orthophosphoric acid, sulphuric acid, methane sulphonic acid, toluenesulphonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumoric acid, malic acid, succinic acid, salicylic acid or acetylsalicyclic acid, The salts of compounds of formula I need not be pharmaceutically acceptable as they are also useful in the preparation of other compounds of formula I and in the separation of stereoisomers of compounds of formula I when the salt ion is also opticall active. In vivo hydrolysable acyl derivatives are those which are converted to compounds of formula I in the body of a patient to whom the acyl derivative has been administered. Compounds of formula I have at least one asymmetric carbon atom, ie the carbon atom bearing the hydroxyl group and R3 and, when 1 and 2 and, when R and R2 are different, the carbon atom bearing R1 and R2 is also asymmetric. The compounds may therefore exist in at least two and often four stereoisomeric forms. The present invention encompasses all stereoisomers of the compounds of formula I whether free from other stereoisomers or admixed with other stereoisomers in any proportion and thus includes, for instance, racemic mixtures of enantiomers, Preferably, the carbon atom bearing the hydroxyl 3 group and R has the R configuration. The most potent compounds of formula I are those wherein R1 and R2 are different and both asymmetric carbon atoms are in the R configuration. The absolute configuration of any compound of formula I may be determined by conventional X ray crystallographic techniques. It is believed that, in the 13C n.m.r. spectrum of compounds of formula I wherein one of R1 and R2is hydrogen and the other is methyl, the diastereoisomer having anti the greater anti obesity and anti hyperglycaemic activity is that for which the signal of the methyl group carbon atom appears at higher field the lower numerical value when expressed in ppm in d6DMSO solution. The paired resonances often appear at approximately 20 ppm less active and slightly below 20 ppm more active down field from tetramethylsilane. Other paired resonances can occur for the carbon atoms attached directly to the nitrogen atom and the carbon which carries the hydroxyl group and R3 Again the paired resonances of the more active diastereoisomer of the investigated compounds appear at the higher field position. The present invention provides a process for producing a compound of formula I or a salt, thereof, which process comprises reducing an oxo group and or a double bond and or a moiety reducible to a group R of a compound of formula 11 EMI6.1 wherein R,R3 R and n are as defined in relation to formula I R11 is R4 or a moiety reducible to a group R4 as defined in relation to formula I R12 is a group R2 as defined in relation to formula I or together with R13 forms a bond R13 is hydrogen or benzyl or together with R12 or R14 forms a bond, R14 is hydrogen or together with R15 forms an oxo group 13 or together with R13 forms a bond, R15 is hydrogen or together with R14 forms an oxo group R16 is hydroxyl or together with R17 forms an oxo group R17 is hydrogen or together with R16 forms an oxo group, provided that there is no more than one oxo group and no more than one bond represented by any of R12 to R178 and optionally thereafter forming a salt of the compound of formula I so formed and or converting the compound of formula I so formed into a further compound of formula I . Where there are two or more reducible groups in the compound of formula git these may be reduced separatel.y in any order or simultaneously. The aforementioned reductions may be effected by conventional chemical or catalytic methods, such as chemical reduction using lithium aluminium hydride, sodium cyanoborohydride or sodium borohydride or boron methyl sulphide or by catalytic hydroa,,enation using catalysts such as palladium on charcoal, or platinum, for instance, as platinum oxide. Reduction by sodium borohydride is conveniently effected in a lower alkanolic solvent such as methanol.or ethanol. The reaction is generally carried out at from 0 200C. Reduction by lithium aluminium hydride is conveniently effected in a dry, ether solvent such as diethyl ether or tetrahydrofuran at ambient or elevated temperature. Catalytic reduction is conveniently effected in a conventional hydrogenation solvent such as a lower alkanol, for instance ethanol. The hydrogenation is generally carried out under hydrogen gas at about 1 atmosphere pressure to about 10 atmosphere pressure and at ambient or elevated temperature. In particular aspects, the present invention provides processes for producing compounds of formula I by reducing a compound of formula IIA EMI7.1 or reducing a compound of formula lIB EMI8.1 or reducing a compound of formula IIC EMI8.2 or the N benzyl derivative thereof or reducing a compound of formula IID EMI8.3 or reducing a compound of formula lIE EMI8.4 wherein R11 is a moiety reducible to a group R4, and R1, R2, R3 R , R5 and n, are as defined in relation to formula I . Suitable groaps for R11 include cyanoalkoxy or amino carbonylalkoxy groups which may be reduced, for instance catalytically or using lithium aluminium hydride or boron methyl sulphide, to provide the corresponding aminoalkoxy group R4. The present invention also provides another process for producing a compound of formula I or a salt thereof which process comprises reacting a compound of formula III EMI9.1 or a compound of formula VIIID as hereinafter defined with a compound of formula IV EMI9.2 wherein R11 R2, R31 R4 R5 and n are as defined in relation to formula I , and optionally thereafter forming a salt of the compound of formula I so formed. The reaction of a compound of formula III with a compound of formula IV is conveniently effected in a solvent such as a lower alkanol, preferably ethanol. The reaction of a compound of formula VIIID with a compound of formula IV is described below. A particular preferred process for producing compounds of formula I comprises the reduction of a compound of formula IIA , especially using sodium borohydride in methanol at ambient temperature. The present invention also provides yet another process for producing a compound of formula I or a salt EMI10.1 with a compound of formula VI EMI10.2 wherein R1, R21 R31 R , R61 A, X and n are as defined in relation to formula I .and Y is a leaving group, such as halogen especially bromine, or tosyloxy. The reaction of a compound of formula V with a compound of formula VI may be effected in a suitable solvent, which may be aqueous or organic, and preferably but not necessarily at elevated temperature. Compounds of formula I may be converted into further compounds of formula I by conventional processes.Thus, for example, the compound of formula I whereinA and or R6 is hydrogen may be derivatised to produce further compounds of formula I . The salts of compounds of formula I may be produced bytreating the compound of formula I with the appropriate acid. Acyl derivatives of compounds of formula I may be produced by conventional methods. Compounds of formula I and salts thereof, produced by the above processes, may be recovered by conventional methods. Compounds of formula I having a single asymmetric carbon atom may, if desired, be separated into individual enantiomers by conventional means, for example by the use of an optically active acid as a resolving agent.Those compounds of formula I having two asymmetric carbon atoms may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallisation from a suitable solvent such as methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means such as by the use of an optically active acid as a resolving agent, Suitable optically active acids which may be used as resolving agents are described in 1Topics in Stereochemistry Vol 6, Wiley Interscience, 1971, Allinger, N.L.and Eliel, WL. Eds. Alternatively any enantiomer of a compound of formula I may be obtained by stereospecific synthesis using an optically pure starting material of known configuration. Compounds of formula II may be produced by reacting a compound of formula VII EMI11.1 wherein Rl,R2,R5and n are as defined in relation to formula I , and Rll is as defined in relation to formula II with a compound of formula VIII 3 R Y VIII wherein R3 is as defined in relation to formula Ij and y is a moiety containing a reactive groupwhich is capable of reacting with the amine of formula YII thus forming a compound of formula II , Typical examples of compounds ol formula VIII are EMI12.1 or its hydrate or hemi acetal of a lower alkanol EMI12.2 wherein Z is a halogen atom, preferably bromine EMI12.3 EMI13.1 andEMI13.2 wherein Z is a leaving group such as halogen or preferably tosylate, Conventional conditions suitable for use with the particular compound of formula VIEl may be used for this reaction. Thus the reaction of a compound of formula VIIIA with a compound of formula VII is conveniently conducted at elevated temperature under conditions resulting in the removal of the water formed during the reaction.A particularly suitable method is to perform the reaction in a solvent, such as benzene, under reflux and azeotropically to remove the water using a Dean and Stark trap. The reaction of a compound of formula VIIIB with a compound of formula VII or its N benzyl derivative is conveniently conducted in a polar organic solvent such as acetonitrile or butanone, at an elevated temperature, for instance under reflux. The reaction of a compound of formula VIlIC with a compound of formula VII is conveniently conducted under standard peptide formation reaction conditions. The reaction of a compound of formula III with a compound of formula VII is conveniently conducted in a solvent such as a lower aikanol, preferably ethanol. The reaction of a compound of formula VIVID with a compound of formula VII is conveniently conducted in a solvent such as dimethylsulphoxide at elevated temperatures, preferably about 50 C for about 3 days. When R11 is a group R4 the reaction between a compound of formula III or VIlID and a compound of formula VII give a compound of formula I directly and such processes form a further aspect of the present invention. By using single enantiomers of a compound of formula VII and a compound of formula VIII such as the compounds VIIIC or III wherein R11 is a moiety reducible to a group R4 a stereospecific synthesis of a compound of formula I or II is achieved. The compound of formula II may then be reduced to a compound of formula I without altering the configuration of the two asymmetric carbon atoms. Thus, for example, a compound of formula VII with the R absolute configuration and a compound of formula III with the R absolute configuration would afford a compound of formula I or II with the RRabsolute configuration.Also a compound of formula VII with the R absolute configuration and a compound of formula VIIIC of the R absolute configuration would afford a compound of formula II and by subsequent reduction afford a compound of formula I with an R ,R absolute configuration. Certain compounds of formula, II may also be produced by reacting a compound of formula IX EMI15.1 with a compound of the formula X EMI15.2 or with a compound of formula XI EMI15.3 R1 2 3 5 wherein R1,R2,R3,R and n are as defined in relation to formula I R11 is as defined in relation to formula II and Z is a leaving group,suitably halogen or tosyloxy, preferably tosyloxy. The reaction of a compound of formula IX with a compound of formula X is conveniently effected under conditions which result in the removal of water formed during the reaction. A particularly suitable method is to perform the reaction in a solvent, such as benzene, under reflux and azeotropically to remove the water using a Dean and Stark trap. The reaction of a compound of formula IX with a compound of formula XI is conveniently effected in a solvent such as dimethylsulphoxide at elevated temperature, preferably about 5O C for about two to three days. It is often convenient to prepare the compound of formula II and reduce it to the desired compound of formula I without isolation of the compound of formula it . A compound of formula I or a pharmaceutically acceptable salt thereof hereinafter the drug may be administered as the pure drug, however, it is preferred that the drug be administered as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier. Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable acyl derivative thereof with a pharmaceutically acceptable carrier therefor. As used herein the terms pharmaceutical composition and pharmaceutically acceptable embrace compositions and ingredients for both human and veterinary use. Usually the compositions of the present invention will be adapted for oral administration although compositions for administration by other routes, such as by injection are also envisaged. Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used. In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, binder, filler disintegrant, wetting agent, lubricant, colourant, flavourant, or the like. Typical carriers may, therefore, comprise such agents as microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate, sucrose and the like. Most suitably the composition will be provided in unit dose form. Such unit doses will normally comprise 0.1 to 500 mg of the drug, more usually 0.1 to 250 mg and favourably 0.1 to 100 mgO The present invention further provides a method for treating obesity in humans or domestic mammals, which method comprises administering an effective, non toxic amount of a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable acyl derivative thereof to obese humans or domestic mammals. Conveniently, the drug may be administered as a pharmaceutical composition as hereinbefore defined, and this forms a particular aspect of the present invention. In treating obese humans the drug may be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be about 0.1 to 1000 mg, and more usually about 1 to 500 mg. In treating obese domestic mammals, especially dogs the drug may be administered by mouth, usually once or twice a day and at about 0.025 mg kg to 2.5 mg kg, for example 0.1 mg kg to 2 mg kg. The present invention further provides a method for treating hyperglycaemia in humans which method comprises administering an effective, non toxic amount of a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable acyl derivative thereof to hyperglycaemic humans. The present invention also provides a method for the treatment of inflammation in humans, which comprises topically administering an effective nontoxic amount of a compound of formula I or a pharmaceutically acceptable salt thereof to humans sutferina inflammation. hu present invention further provides a m.thotl C I inhibiting platelet aggregation in humans, which comprises administering an effective non toxic about of a compound of formula I or a pharmaceutically acceptable salt thereof, to a human in need of such treatment. inZenicnl.ly, the drug may be administered as a pharmaceutical composition as hereinbefore defined, and this forms a particular aspect of the present invention. The drug may be taken in doses such as those described above for treating obese humans. The invention will now be illustrated with reference to the following Examples, which are not intended to limit the scope in any way. EXAMPLE 1 N r 2 4 2 Methylaminoethoxv Phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlorideEMI19.1 A mixture of 2 hydroxy 2 3 trifluoromethylphenyl ethanamine 300 g and l 4 2 methylaminoethoxy phenyl propan 2 one 3.0 g in dry benzene was heated under reflux using a Dean and Stark head for two hours, cooled and evaporated to dryness. The residue was dissolved in methanol 50 ml and hydrogenated over platinum oxide 50 mg at normal temperature and pressure, filtered through diatomaceous earth and evaporated to dryness.Chromatography of the residue on silica gel in 5 methanoldichloromethane gave an oil. Conversion to the dihydrochloride salt by passage of hydrogen chloride gas into an ethereal solution of the oil gave methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride. M.P. 21460C methanol ethylacetate as a 73 27 mixture of diastereoisomers. 1 nmr DMSO d6 8.9 3H,d,J 6Hz , 7.4 3H,s , 6.6 7.0 7H, complex , 5.8 2H,t , 4.8 lH,m , 3.55 lH,exchangeswith D20 , 3.05 2H,d , 2.8 2H,d , 2.15 2.45 4H, complex , 0.65 4H, exchanges with D20 . EXAMPLE la Recrystallisation of the above material twice from methanol gave a sample, m,p. 258 2620C, of 91 9 mixture of diastereoisomers. EXAMPLE 2 N r 2 4 2 Dimethylaminoethoxy phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlorideEMI21.1 Starting from 2 hydroxy 2 3 trifluoromethylphenyl ethanamine 2.5 g and 1 4 2 dimethylaminoethoxy phenyl propan 2 one 2.5 g N 2 4 2 dimethylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, M.P. 218 223 0C methanolethylacetate , was prepared, as a 85 15 mixture of diastereoisomers by an analogous procedure to that described in Example 1. 1 nmr t DMSO d6 8.85 3H,d , 7.15 6H,s , 6.3 7.0 7H,m , 5.6 2H,t , 4.75 lH,m , 3o5 1H, exchanges with D20 , 3.05 2H,d , 2.75 2H,d , 2.1 2.45 4H,m , 005 l.O 3H, broad exchange with D20 EXAMPLE 3N 2 4 2 Methylsulphonylaminoethoxy phenyl 1 methylethyl 1 2 hedroxy 2 3 trifluoromethylphenyl ethanamineEMI22.1 Starting from 2 hydroxy 2 3 trifluoromethylphenyl ethanamine 2.7 g and 1 4 2 methylsulphonylaminoethoxy phenyl propan 2 one 3.2 g N 2 4 2 methylsulphonylamino ethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoro methylphenyl ethanamine M.P. 96 100 C methyl ether hexane was prepared as a 56 44 mixture of diastereoisomers by an analogous procedure to that described in Example 1. nmr CDC13 t D20 8.95 3H,dR 6Hz , 7.0 7.6 5H, complex , 7.05 3H,s , 6.55 2H,t , 5.95 2H,t 5.4 lH,m , 3o2 2H,d , 2.9 2H,d , 2.3 2.6 4H, complex . EXAMPLE 4N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 1 2 hydroxy 2 2 benzofuranyl ethanamine dihydrochlorideEMI23.1 A mixture of 2 2 benzofuranyl 2 hydroxyethanamine 0. 74g and l 4 2 methylaminoethoxy phenyl propan 2 one 0.87g in benzene was heated under reflux using a Dean and Stark head for two hours, cooled, and evaporated to dryness.The residue was dissolved in methanol 60m1 and sodium borohydride l.Og was added portionwise, with stirring, at 0 C. The reaction mixture was stirred for one hour, then the methanol was evaporated and water was added to the residue, extracted with ethyl acetate X2 dried magnesium sulphate and evaporated to dryness. The residue was purified by column chromatography on silica gel with 7 methanol in dichloromethane as eluent. The oil so obtained was converted to its dihydrochloride salt by addition of methanolic hydrogen chloride to give N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 2 benzofuranyl ethanamine dihydrochloride, m.p. 213 2230C methanol ethyl acetate of analytical purity. H nmr. ln DMSO d6 8.85 3H,d , 7.4 3H,s , 6.25 7.0 7H,complex , 5.7 2H,t , 4.65 1H,m , 3.4 1H,exchanges with D20 , 2.2 3 9H complex , 0,2 10 4H, exchanges with D 0 . EXAMPLE 5 N 2 3 Fluoro 4 2 meth laminoetho ben l methylethyl 1 2 hydroxy 2 3 chlorophenyl ethanamine dihydrobromide.EMI24.1 A mixture of 2 hydroxy 2 3 chlorophenyl ethanamine 1.3g and l 3 fluoro 4 2 methylaminoethoxy phenyl propan 2 one 1.6g in dry benzene was heated under reflux using a Dean and Stark head for two hours. cooled and evaporated to dryness. The residue was dissolved in methanol, cooled with ice and sodium borohydride 2.or was added in portions over fifteen minutes, with stirring after stirring for a further hour, the solvent was evaporated, Water was then added to the residue and the residue extracted with ethyl acetate. The extract was dried magnesium sulphate and evaporated to dryness. Chromatography of the residue on silica gel eluting with 10 methanol in dichloromethane gave an oil which was converted to its dihydrobromide salt by addition of hydrogen bromide in methanol.Crystallisation from ethyl acetate gave N 2 3 Fluoro 4 2 methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrobromide, m.p. 207 14 , of analytical purity. 1H mnr. t DMSO d6 8.85 3H,d , 7.3 3H,S , 6.3 7.2 7H,m , 5.65 2H,t , 4.9 lH,m , 3.8 1H, exchanges with D20 , 2.4 3.1 7H, complex , 1.1 4H, exchanges with D2 o . EXAMPLE 6 N 2 4 2 Methylaminoethoxy Phensl l methylethyl 2 hydroxv 2 3 ethylphenyl ethanamine dihydobromide EMI25.1 A mixture of 2 hydroxy 2 3 ethylphenyl ethanamine 2.39g and 1 2z. 2 methylaminoethoxy phenylupropan 2 one 3.0g in. dry benzene was heated under reflux for 2 hours using a Dean and Stark head, cooled and the solvent evaporated.The residue was dissolved in ethanol and hydrogenated over platinum oxide at normal temperature and pressure, filtered through diatomaceous earth and evaporated to dryness.Chromatography of the residue on silica gel in methanol chloroform ammonia 8 92 0.5 gave an oil. Conversion to the dihydrobromide salt by passage of hydrogen bromide gas into an ethereal solution of the oil gave methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 ethylphenyl ethanamine dihydrobromide mp 228 2320C methanol ethylacetate as a 60 40 mixture of diastereoisomers. H nmr z DMSO d H nmr DMSO d6 8.9 3H,d , 8.8 3H,t,J 7Hz , 7.4 3H,s 2Hm , 63 7,0 7H, , 5.75 2H,t , 5.0 lH,m , 3.9 1H, broad, disappears with D20 , 3.2 2.65 8H,m , 1.2 4H, broad, disappears with D20 2 EXAMPLE 7 N i2 4 2 Methylaminoethoxy phenyl 1 methylethyll 2 hydroxv 2 2 flUorOPhenYl ethanamine dihydrobromideEMI26.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 2 fluorophenyl ethanamine and 1 L4 2 methylaminoethoxy phenylupropan 2 one.N 2 4 2 methylaminoethoxy phenyil methylethyj 2 hydroxy 2 2 fluorophenyl ethanamine dihydrobromide mp 252 2580C methanol ethylacetate was isolated as a 58 42 mixture of diastereoisomers.1H nmr r DMsO d6 8.85 3H,d , 7.5 3H,s , 7.2 6.2 7H,m , 5.85 2H,t , 4.8 lH,t , 3.1 2H,d , 3.0 2.3 6H,m , 1.7 4H,broad, disappears with D20 . EXAMPLE 8N C 4 2 Methyl aminoethoxy phenyl l methylethy 2 hydroxy 2 3 bromophenyl ethanamine dihydrobromideEMI27.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 3 bromophenyl ethanamine and 1 4 2 methylaminoethoxy phenyl propan 2 one. 2 4 2 methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 3 bromophenyl ethanamine dihydrobromide 0 mp 198 199 C methanol ethylacetate was isolated as a 60 40 mixture of diastereoisomers. H nmr DMSO d H nmr DMSO d, 8.85 3H,d , 7.35 3H,s , 7A 6,2 7H,m , 5.72 2H,t 4.9 lH,m , 3.7 lH,broad,disappears with D20 , 3.05 2H,d , 2.8 2H,m , 2.7 2.25 4H,m , 1.2 4H, broad, disappears with D20 . EXAMPLE 9N 2 4 2 Methylaminoethoxy phenyi l methylethyi 2 hydroxy 2 3 f luorophenyl e thanamine dihydrobromideEMI28.1 This compound was prepared in an analogous manner to that described in Example 5 using 2 hydroxy 2 3 fluorophenyl ethanamine and l C4 2 methylaminoethoxy phenyl propan 2 one. Chromatography on silica gel eluting with methanol chloroform ammonia 8 92 1 gave an oil from which N 2 4 2 methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 fluorophenyl ethanamine dihydrobromide mp 202 2030C methanol ethylacetate was obtained as a 57 43 mixture of diastereoisomers. H nmr DMSO d6 6 8.8 3H,d , 7.3 3H,s , 7.4 6.2 7H,m , 5.7 2H,t , 4.8 lH,m , 3.75 1H, disappears withD2O , 3.0 2H,d , 2.9 2.3 6H,m , 1.1 4H, disappears with D20 . EXAMPLE 10N r 4 2 Methylaminoethoxy phenyl l methylethyl 2 hydroxy 2 phenylethanamine dihydrobromideEMI29.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 phenylethanamine and 1 C4 2 methylaminoethoxy phenypropan 2 one.N 2 4 2 methylaminoethoxy phenyl i methylethyl 2 0 hydroxy 2 phenylethanamine dihydrobromide mp 205 209 C methanol ethylacetate was obtained as a 57 43 mix urge of diastereoisomers.H nmr t DMSO d6 8.8 3H,d , 7.3 3H,s , 7.4 6.2 7H,m 5.75 2H,t 5.1 1H,m , 3.5 1H, disappears with D20 , 3.05 2H,d , 2.75 2H,d , 2.5 5H,m , 1.2 4H, broad, disappears with D2 0 . EXAMPLE 11 N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 1 2 hydroxy 2 2 fluoro 3 chlorophenyl ethanamine dihydrochlorideEMI30.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 2 fluoro 3chlorophenyl ethanamine and 1 4 2 methylaminoethoxy phenyl propan 2 one. N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 2 fluoro 3 chlorophenyl ethanamine dihydrochloride, mp 232 2340C methanol ethyl acetate , was isolated as a 49.51 mixture of diastereoisomers. 1H nmr r DMSO d6 8.8 3H,d , 7.4 3H,s , 6.3 7.4 7H,m , 5.8 2H,t , 4.5 1H,m , 3.45 lH,d, disappears with D20 , 3.0 2H,d , 2.75 2H,d , 2.2 2.75 3H,m , 0.5 4H,broad, disappears with D20 . EXAMPLE 12 N t2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 4 chiorophenyl ethanamine dihydrochlorideEMI31.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 4 chlorophenyl ethanamine and 1 4 2 methylaminoethoxy phenyl propan2 one. N 2 4 2 Methylaminoethoxy phenyl 1 methyl ethyl 2 hydroxy 2 4 chlorophenyl ethanamine dihydrochloride, mp 232 2460C methanol ethyl acetate was isolated as a 60 40 mixture of diastereoisomers. H nmr DMSO d6 8.8 3H,d , 7.4 3H,s , 6.6 7.4 7H,m , 5.8 2H,t , 4.8 1H,m , 3.7 1H, broad, disappears with D20 , 3.1 2H,d , 2.8 2H,d , 2.5 4H,s , 0.6 4Hr broad, disappears withD20. EXAMPLE 13 N 2 4 2 Benzylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride monohydrateEMI32.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 chlorophenyl ethanamine and 1 4 2 benzylaminoethoxy phenyl propan 2 one. N 2 4 2 Benzylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride 0 monohydrate, mp 217 222 C methanol ethyl acetate was isolated as a 47 53 mixture of diastereoisomers. Hnmr t DMSO d6 8.8 3H,d , 6.6 7.4 7H,m , 5.8 2H,s , 5.7 2H,t , 4.9 1H,m , 3.7 1H, broad, disappears with D20 , 3.1 2H,d , 2.8 2H,d , 2.3 2.7 9H,m , 1.1 1H, broad, disappears withD20 , 0.2 3H, broad, disappears with D20 . EXAMPLE 14 N 2 4 2 1 piperidine ethoxv phenyl 1 methyleth 2 hydroxy 2 3 chlorophenyl ethanamine dihydroch lor ide EMI33.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 chlorophenyl ethanamine and l 4 2 l piperidine ethoxy phenyl propan 2 one. N 2 4 2 1 Piperidine ethoxy phenyll 1 methylethyll 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride, mp 211 213 C methanol ethyl acetate was isolated as a 45 55 mixture of diastereoisomers. Hnmr Q DMSO d6 8.8 3H,d , 8.0 8.7 6H,m , 6.2 7.4 11H,m , 5.55 2H,t 4.8 1H,m , 3.55 1H, broad, disappears with D20 , 3.0 2H,d , 2.75 2H,d , 2.4 2.6 4H,m , 0.95 1H, broad, disappears with D20 , 0.2 1H, broad, disappears with D20 , 1.5 1H, broad, disappears with D20 . EXAMPLE 15 N 2 4 2 1 Homopiperidine ethoxy phenyl l methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlorideEMI34.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethyl phenylethanamine and 1 4 2 1 homopiperidine ethoxy phenyl propan 2 one. N 12 4 2 1 Homo piperidine ethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, mp 179 183 C methanol ethyl acetate was isolated as a 40 60 mixture of diastereoisomers. Hnmr t DMSO d6 8.8 3H,d , 8.0 8.6 8H,m , 6.3 7.4 11H,m , 5.55 2H,t , 4.75 1H,m , 3.5 1H, broad, disappears with D20 , 3.0 2H,d , 2.75 2H,d , 2.05 2.35 4H,m , 0.95 1H, broad, disappears with D20 , 0.15 1H, broad, disappears withD20 , 1.9 1H, broad, disappears with D20 . EXAMPLE 16N 2 4 2 Ethoxycarbonylaminoethoxy phenyl 1 methyl ethyll 2 hydroxy 2 3 chlorophenyl ethanamine EMI35.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 chlorophenyl ethanamine and 1 4 2 ethoxycarbonylaminoethoxy phenyl propan 2 one. N 2 4 2 Ethoxycarbonylaminoethoxy phe 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine, mp 99 1060C ether hexane as a 40 60 mixture of diastereoisomers. Hnmr CDCl3 8.9 3H,d , 8.8 3H,t , 6.9 7.7 6H,m,1 disappears withD20 , 6.45 1H,dt,collapses to t with D20 , 6.0 2H,t , 5.9 2H,q , 5.55 1H,m , 4.85 1H, broad, disappears with D20 , 3.15 2H,d , 2.95 2H,d , 2.8 2.6 4H,m . EXAMPLE 17N 2 4 2 Methylaminocarbonylaminoe hoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamineEMI36.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydrdxy 2 3 trifluoro methylphenyl ethanamine and 1 4 2 methylaminocarbonyl aminoethoxy phenyl propan 2 one. N 2 4 2 Methyl amino carbonylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine was isolated as the free base, mp 131 139 C ethylacetate as a 15 85 mixture of diastereoisomers. Hnmr DMSO d6 9.1 3H,d , 7.8 8.7 1H, broad , 7.45 3H,d , 7.0 7.4 5H,m , 6.65 2H,dt , 6.1 2H,t , 5.3 lH,m , 4.5 1H, broad , 4.15 1H,q , 3.9 lH,t , 3.15 2H,d , 2.9 2H,d , 2.2 2.6 4H,m . EXAMPLE 18N 2 4 2 Benzylaminoethoxy phenyl 1 methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine EMI37.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 benzylaminoethoxy phenyl propan 2 one. Column chromatography on silica with methanol dichloromethane 5 95 as eluent gave an oil which was crystallized from ethylacetate hexane to give N 2 4 2 benzylaminoethoxy phenyl 1 methylethyi 2 hydroxy 2 3 trifluoromethylphenyl ethanamine, mp 0 67 81 C. Hnmr t CDCl3 8.9 3H,d , 6.9 7.6 1OH,complex,3H disappears with D2O , 6.15 2H,s , 5.95 2H,t , 5.3 1H,m , 3.25 2H,d , 2.95 2H,d , 2.25 2.7 9H, complex . EXAMPLE 19N 2 4 2 Aminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, dihydrateEMI38.1 The compound of Example 18 0.95g in ethanol 30ml containing palladium on charcoal 10 w w was hydrogenated at ambient termperature and pressure until hydrogen uptake ceased. The mixture was filtered through diatomaceous earth and evaporated to give N 2 4 2 amino ethOxy phenyl 1 methylethyll 2 hydroxy 2 3 trifluoro methylphenyl ethanamine dihydrochloride, dihydrate, mp 223 2290C methanol ethyl acetate , as a 61 39 mixture of diastereoisomers. Hnmr t DMSO d6 D20 8.9 3H,d , 6.5 7.6 complex , 4.8 1H,m , 3.2 2H,d 2.8 2H,d , 2.2 4H1 complex . EXAMPLE 20 N 2 4 2 Ethoxycarbonylaminoethoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamineEMI39.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 ethoxycarbonylamino ethoxy phenyl propan 2 one. Chromatography on silica gel using methanol dichloromethane 5 95 as eluent gave an oil which crystallized to give N 2 4 2 ethoxycarbonyl aminoethOxy phenyl 1 methylethyl 2 hydroxy 2 3 tri fluoromethylphenyl ethanamine, mp 84 87OC ether hexane , as a 91 9 mixture of diastereoisomers. Hnmr t CDC13 8.95 3H,d , 8.8 3H,t , 6.9 7.65 7H,2H disappears withD20 , 6.5 2H,dt , 5.8 6.2 4H, complex , 5.4 1H,m , 5.0 1H, disappears with D20 , 3.25 2H,d , 2.95 2H,d , 2.5 4H, complex . EXAMPLE 21N 2 4 2 Acetylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine EMI40.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 acetylaminoethoxy phenyl propan 2 one. Chromatography on silica gel using methanol dichloromethane 5 95 as eluent gave N 2 4 2 acetylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine, mp 78 84OC ethyl acetate ether , as a 43 57 mixture of diastereoisomers. Hnmr t CDCl3 8.95 3H,d , 8.05 3H,s , 6.9 7.65 7H,complex,2H disappears with D20 , 6.4 2H,dt , 6.05 2H,t , 5.4 1H,m , 3.95 1H, broad, disappears with D20 , 3.25 2H,d , 2.95 2H,d , 2.45 4H,m . EXAMPLE 22 N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochlorideEMI41.1 This was prepared in an identical manner to the compound described in Example 6 using 2 hydroxy 2 3 chlorophenyl ethanamine and 1 4 2 methylaminoethoxy phenyl propan 2 one. N t2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride, mp 220 226 C methanol ethyl acetate , was isolated as a 58 42 mixture of diastereoisomers. Hnmr t DMS0 d6 8.85 3H,d , 7.4 3H,s , 6.5 7.3 7H,complex , 5.8 2H,t , 4.85 1H,m , 3.65 lH, disappears with D20 , 3.05 2H,d , 2.8 2H,d , 2.4 2.6 4H, complex 0.65 4H, disappears with D20 EXAMPLE 23 N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, RS,SR diastereoisomerEMI42.1 To a solution of the RS,SR diastereoisomer of N 2 4 2 methylaminocarbonylmethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine 2.48g in dry tetrahydrofuran 50ml was added borane methylsulphide 5ml dropwise under nitrogen. The mixture was stirred at ambient temperature for 20 min and then heated under reflux for 4.5h.After cooling a solution of methanol 15ml in tetrahydrofuran 30ml was added dropwise over 0.5h. The solution was allowed to stand overnight at room temperature, heated under reflux for 1.5h, cooled and hydrogen chloride gas passed through the solution.Ether 50ml was added and the solid filtered to give N 2 4 2 methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, RS,SR diastereoisomer, mp 237 240 C, as a 5 95 mixture of RR,SS RS SR diastereoisomers. HnmrIdentical with that of Example 1. EXAMPLE 24 N 2 4 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride RR,SS diastereoisomerEMI43.1 Starting with the RR,SS diastereoisomer of N 2 4 2 methylaminocarbonylmethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and following the procedure described in Example 23, N 2 4 2 methyl aminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoro methylphenyl ethanamine dihydrochloride, RR,SS diastereoisomer, mp 263 266 0C was obtained as a 97 3 mixture of RR,SS RS,SR diastereoisomers. HnmrIdentical with that of Example 1. EXAMPLE 25N 2 4 2 l Pyrrolidine ethoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlor ide EMI44.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 1 pyrrolidine ethoxy phenyl propan 2 one. N 12 4 2 1 Pyrrolidine ethoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 tri fluoromethylphenyl ethanamine dihydrochloride, mp 214 231 0C methanol ethyl acetate was isolated as a 17 83 mixture of diastereoisomers. Hnmr r DMSO d6 8.8 3H,d , 8.1 4H,broad s , 7.7 6.3 11H, complex , 5.65 2H,t , 4.75 1H,m , 3.55 1H, broad, disappears with D20 , 3.1 2H,d , 2.8 2H,d , 2.5 2.1 4H,m , 0.9,0.15, 1.5 3H,all disappear with D20 . EXAMPLE 26 N 2 4 2 1 Piperidine ethoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride monohydrateEMI45.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 t4 2 1 piperidine ethoxy phenyl propan 2 one. N 2 4 2 1 Piperidine ethOxy phenyl 1 methylethyll 2 hydroxy 2 3 tri fluoromethylphenyl ethanamine dihydrochloride monohydrate, mp 176 185 C methanol ethyl acetate was isolated as a 55 45 mixture of diastereoisomers. Hnmr DMSO d6 8.8 3H,d , 8.7 7.9 6H, complex , 7.5 6.3 11H, complex , 5.5 2H,t , 4.7 lH,m , 3.5 lH, disappears with D20 , 3.1 2H,d , 2.75 2H,d , 2.5 2.1 4H,m , 0.8,0.0, 1 .5 3H, all disappear with D20 . EXAMPLE 27 N 2 4 2 EthYlaminOethoxo Phenyl 1 methelethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlorideEMI46.1 This was prepared in an analogous manner to the compound described in Example 23 starting from N 2 4 2 ethylaminocarbonylmethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine. N. 2 4 2 Ethyl aminoethOxy phenyl 1 methylethyl 2 hydroxy 2 3 tri fluoromethylphenyl ethanamine dihydrochloride, mp 2372420C methanol ethyl acetate was isolated as a 66 34 mixture of diastereoisomers. Hnmr DMSO d6 8.9 3H,d , 8.8 3H,t , 7.5 6.3 9H, complex , 5.75 2H, t , 4.75 1H,m , 3.5 1H, disappears with D20 , 3.05 2H, d , 2.75 2H,d , 2.4 2.1 4H,m , 0.5 4H disappears withD20 EXAMPLE 28 N 2 4 2 Methylaminoethoxy phenyl 1 methylethyll 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride RR,SS diastereoisomerEMI47.1 N 2 4 Carbomethoxymethoxypiienyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine hydrobromide RR,SSI diastereoisomer of 97 diastereoisomeric purity was reacted with methylamine by an analogous procedure to that described in Description 18.Subsequent reduction of the amide formed above with borane methyl sulphide in dry tetrahydrofuran by an analogous procedure to that described in Example 23 gave N 2 4 2 methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride as its RR,SS .diastereoisomer of 95 diastereoisomeric purity, mp 232 40C MeOH EtOAc , of analytical purity. HnmrIdentical with that of Example 22. EXAMPLE 29N 2 3 2 Methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochlorideEMI48.1 N 2 3 Carbomethoxymethoxyphenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine was reacted with methylamine by an analogous procedure to that described in Description 18. Subsequent reduction of the amide formed above with borane methyl sulphide in dry tetrahydrofuran by an analogous procedure to that described inExample 23 gave N L2 3 2 methylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine dihydrochloride, mp 202 5 C MeOH EtOAc as a 75 25 mixture of diastereoisomers.1Hnmr DMSO d6 8.9 3H,d , 7.4 3H,s , 6.3 7.3 7H, complex , 5.75 2H, t , 4.9 1H,m , 3.65 1H, exchange with D20 , 2.4 3.2 8H, complex , 0.65 4H, exchange with D20 . EXAMPLE 30 N C2 14 2 1 Morpholine ethoxy phenyl methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanarnine EMI49.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 1 morpholine ethoxy phenyl propan 2 one. N 2 4 2 1 Morpholine ethOxy phenyl 1 methylethyll 2 hydrOxy 2 3 trifluOro methylphenyl ethanamine, mp 96 106 0C ethyl acetate ether was isolated as an 18 82 mixture of diastereoisomers. Hnmr t DMSO d6 8.8 3H,d , 7.7 7.3 11H, complex , 6.8 2H, disappears with D20 , 6.6 6.4 4H, complex , 6.0 2H,t , 5.34 1H, m , 3.3 2H,d , 2.9 2H,d , 2.5 2.34 4H,m EXAMPLE 31 N 2 t 2 Benzylaminopropoxv phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamineEMI50.1 This was prepared in an identical manner to the compound descried in Example 5 using 2 hydroxy 2 3 trifluoro methyphenyl ethanamine and 1 4 2 benzylaminopropoxy phenylpropan 2 one. N 2 4 2 Benzylaminopropoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine, mp 81 920C hexane was isolated as a 94 6 mixture of diastereoisomers. Hnmr tCDCl3 8.9 H,d , 8.8 3H,d , 7.8 6.6 9H,complex , 6.15 2H, d, 2H,s , 5.3 1H,m , 3.2 2H,d , 2.9 2H,d , 2.6 SH, s , ..5 2.3 4H,m EXAMPLE 32 N 1 2 4 Aminopropoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine EMI51.1 This was prepared from the compound of Example 31 as the dihydrochloride salt using the hydrogenolysis conditions described in Example 19. N 2 4 2 Aminopropoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine was isolated as an oil. Hnmr t CDCl3 8.85 3H,d , 8.8 3H,d , 7.7 6.8 10H, complex , 6.25 2H, d , 5.25 lH,m , 3.2 2H,d , 2.9 2H,d , 2.6 2.2 4H,m . EXAMPLE 33N 2 4 6 Methylaminohexyloxy phenyS methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochlorideEMI52.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 6 methylaminohexyloxy phenyl propan 2 one. N 2 4 6 Methylaminohexyloxy phenyl 1 methylethyll 2 hydroxy 2 3 trifluoromethylphenyl ethanamine dihydrochloride, mp 165 171 C methanolethylacetate ether was isolated as a 50 50 mixture of isomers. IInmr DMSO d6 8.85 3H,dd , 8.6 4H,m , 8.38 4H,m , 7.55 3H,s , 7.3 3H,m , 7.0 6.3 4H,m , 6.15 2H,t , 4.75 1H,m , 3.6 1H, broad, disappears with D20 , 3.15 2H,d , 2.85 2H,d 2.6 2.1 4H,m , 0.8 3H, broad 0.2 1H, broad , all dis appear with D20 . EXAMPLE 34N 2 4 2 Aminoethoxy phenyl ethyl 2 hydroxy 2 3 tri fluoromethylphenyl ethanamine EMI53.1 A solution of N 2 4 cyanomethoxy phenyl ethyl 2hydroxy 2 3 trifluoromethylphenyl ethanamine 1.89g in dry tetrahydrofuran was added dropwise under nitrogen to lithium aluminium hydride 0.4g in dry tetrahydrofuran.The solution was heated under reflux for lh at the end of the addition. Water 0.4ml , 2M sodium hydroxide 0.4ml followed by water 1.2ml was added dropwise, the mixture filtered and the filtrate dried magnesium sulphate .Filtration and evaporation of the solvent gave N 2 4 2 aminoethoxy phenyl ethyl 2 hydroxy 2 3 trifluoromethyl phenyl ethanamine, mp 63 670C ethyl acetate ether . Hnmr DMSO d6 7.6 7.2 6H,complex , 7.2 2H,t , 7.2 6.7 4H,broad, disappears with D20 , 6.15 2H,t , 5.25 lH,m , 3.15 2H,d , 2.9 2H,d , 2.5 2.2 4H,m . L XA1IPLE 35 N 3 4 2 DimethylaminOethoxy phenyl 1,1 dimethylpropyl 2 hydroxy 2 phenylethanamine dihydrochlorideEMI54.1 A mixture of 4 4 2 dimethylaminoethoxy phenyl 2 methylbutan 2 amine 2.08g and phenylglyoxal 1.26g was heated under reflux in benzene for 4h using a Dean andStark apparatus. The solvent was evaporated, replaced with methanol and sodium borohydride 3g added portionwise.The methanol was evaporated, the residue partitioned between ether and water and the ether layer dried magnesium sulphate . Filtration and evaporation of the solvent gave an oil which was chromatographed on Kieselgel 60. solution with methanol chloroform 4 96 gave N 3 4 2 dimethylaminoethoxy phenyl 1t1 dimethylpropyla 2 hydroxy 2 phenylethanamine dihydrochloride after treatment with ethereal hydrogen chloride, mp 221 223 0C methanolethyl acetate . Hnmr t DMSO d6 8.6 6H, s , 8.3 7.9 2H,m , 7.4 2H,m , 7.2 6H,s , 7.0 2H,m , 6.55 2H,t , 5.65 2H,t , 4.9 1H,m , 3.8 1H, disappears with D20 , 3.05 2H,d , 2.8 2H,d , 2.55 5H, m , 1.3 1H ,0.2 1H , 1.1 1H all disappear with D201. EXAMPLE 36N 2 4 2 Dimethylaminoethoxy phenyl 1 methylethyll2 hydroxy 2 3 trifluoromethylphenyl ethanamine fumarateEMI56.1 This was prepared in an identical manner to the compound described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 2 diethylaminoethoxy phenyl propan 2 one. N 2 4 2 Dimethylaminoethoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoromethyl phenyl ethanamine fumarate, mp 136 1 380C methanolethylacetate was isolated as a 52 48. mixture of diastereoisomers. Hnmr , DMSO d6 9.0 6H,t 3H,d , 7.3 4H,q , 7.1 7H, complex , 5.9 2H,t , 4.95 1H,m , 3.45 2H,s , 3.15 2H,d , 2.85 2H, d , 2.5 1.8 4H,m 4H, disappears with D20 . EXAMPLE 3 N 2 4 Cyanomethoxy phenyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamine EMI57.1 A mixture of 2 hydroxy 2 3 trifluoromethylphenyl ethan amine 1.45g , triethylamine 1.5ml and 2 4 cyanomethoxy phenyl ethanol, 4 toluene sulphonate 2.0g was stirred in dimethyl sulphoxide for 5 days at ambient temperature. The mixture was poured into water and extracted with ethyl acetate. The combined ethyl acetate layers were washed with water x2 and dried magnesium sulphate . Evaporation of the solvent gave an oil which was chromatographed on Kieselgel 60. Elution with methanol chloroform 2 98 gave the title compound as an oil. Hnmr t CDCl3 7.4 2H,m , 7.2 6H,m , 5.25 2H, lHm , 3.15 2H,d , 2.8 2H,d , 2.6 2.3 4H,m . EXAMPLE 38N 2 4 Cyanomethoxy phenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamineEMI58.1 This was prepared in an identical manner to the compound described in Example 1 using 2 hydroxy 2 3 chlorophenyl ethanamine and l 4 cyanomethoxyMphenyl propan 2 one. N L2 4 cyanomethoxy phenyl l methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine m.p. 74 79 C ether hexane was isolated as a 31 69 mixture of diastereoisomers.H nmr CDCl3 8.9 3H,d 6.9 7.6 5H, complex 6.45 2H, broad singlet, exchanges with D20 5.1 5.3 3H, complex 2.5 3.3 8H, complex . DESCRIPTION 1 l r4 2 Hedroxyethoxy phenyl1propan 2 one ethylene ketalEMI59.1 A mixture of l 4 carbomethoxymethoxyphenyl propan 2 one ethylene ketal 5.0 g in methanol 70 ml was treated portionwise with sodium borohydride 5.0 g with stirring over 30 minutes then stirred for a further 30 minutes.Water 150 ml was added and the mixture extracted with dichloromethane, dried magnesium sulphate and evaporated to dryness to give the title compound. 1 nmr. C CDC13 8.7 3H,s ,7.5 lH , 7.15 2H,s , 5.8 6.55 8H, complex , 3.15 2H,d , 2.8 2H,d . DESCRIPTION 2 l 4 2 Hvdroxvethaxy phenyllpropan 2 on ethylene ketal p toluene sulphonic esterEMI60.1 p Toluenesulphonyl chloride 3.8 g was added portionwise to a stirred solution of 1 4 2 hydroxyethoxy phenylgpropan 2 one ethylene ketal 4.5 g in pyridine 100 ml at OOC, stirred for 2 hours at OOC, one hourat room temperature, poured into iced water 250 ml and extracted with diethyl ether. The extracts were washed with dilute hydrochloric acid, water, dried magnesium sulphate , filtered and evaporated to dryness to give the title compound, M.P. 68 70 C. H nmr C CDCl3 8.85 3H,s , 7.57 3H,s , 7.25 2H,s , 6.22 4H,m , 5,79 4H,dd , 3.33 2H,d , 2.91 2H,d , 2.57 2H,d , 2Q20 2H,d . DESCRIPTION 3 l 4 2 Methylaminoethoxy phenyllpronan 2 one EMI61.1 Gaseous methylamine was slowly added to a stirred solution of l 4 2 hydroxyethoxy phenyl propan 2 one ethylene ketal p toluenesulphonate ester 4.0 g in dimethyl sulphoxide 100 ml over 2 hours at room temperature.After stirring for a further 2 hours, the mixture was poured into water 900 ml , extracted with diethyl ether, washed with water, dried magnesium sulphate and evaporated to give the title compound as its ethylene ketal, 1 nmr i CDC13 8.7 3H,s , 8.3 lH,s , 7o.5 3H,s , 7.15 2H,s 1, 7.0 2H,m , 5.S 6.35 6H,m , 3.2 2H,d ,. 2.8 2H,d . Deketalisation to the title compound was effected in the usual manner with methanol 2M hydrochloric acid at room temperature. DESCRIPTION 4 l f4 2 Dimethylaminoethoxy phenyl1ProPan 2 oneEMI62.1 l 4 2 Dimethylaminoethoxy ptlenyl3propan 2 one ethylene ketal was prepared from l 4 2 hydroxyethoxy phenyl jprQDan 2 one ethylene ketal p toluene sulphonic ester by an analogous procedure to that described inDescription 3. H nmr t CDCC3 8.7 3H,s , 7.65 6H,s , 7.3 2H,m , 7.15 2H,s , 5,8 6.35 6H,m , 3.14 2H,d , 2.8 2H,d . Deketalisation was effected with methanol 2M hydrochloric acid at room temperature in the usual manner. DESCRIPTION 5 l r4 2 MethYlsulDhonvlaminoethoxy phenyllpropan 2 one EMI63.1 A mixture of l 4 hydroxyphenyl propan 2 one ethylene ketal 3.88 g , N 2 bromoethyl methysulphonamide 4 44 g and sodium hydroxide 1.5 g in water 30 ml was heated under reflux for 90 minutes, cooled, diluted with water and extracted with ethylacetate. T he extracts were dried magnesium sulphate and evaporated to give the title compound as its ethylene ketal. Deketalisation in methanol2M hydrochloric acid was effected in the usual manner. DESCRIPTION 6 l 3 Fluoro 4 hydroxyphenyl propan 2 one i 2 Chloro l 3 f luoro 4 hydroxyphenyl propan l one 2 Chloropropionyl chloride 55g was added, dropwise, under nitrogen gas, to a stirred slurry of aluminium chloride 116g in 1,2 dichloroethane 200ml . The mixture was stirred at ambient temperatures for 15 minutes. 2 Fluoroanisole 50g was added dropwise to the stirred mixture the reaction mixture was stirred at ambient temperatures for 16 hours and poured onto an ice water mixture.The organic layer was separated and the aqueous layer was extracted with l,2 dichloroethane. The combined organic layers were washed with water, dried magnesium sulphate and concentrated to give 2 Chloro l 3 fluoro 4 hydroxnphenyl propan l one as an oil which was used in the next stage without purification.ii l 3 Fluoro 4 hydrÃxyphenyl propane 1,2 diol Potassium acetate 40g then glacial acetic acid 20ml and then sodium iodide l0g were added to a solution of 2 chloro l 3 fluoro 4 hydroxyphenyl propan l one 80g in acetone 350my . The mixture was stirred and heated under reflux for 4 hours, cooled, and treated with water 250my . The acetone was evaporated and the aqueous residue was extracted into dichloromethane. The organic phase was washed with sodium bicarbonate solution, dried magnesium sulphate and concentrated by removal of the solvent under reduced pressure. The residual oil was dissolved in ethanol 400ml , cooledin ice and treated with excess sodium borohydride 15a . The solution was stirred for 2 hours at ambient temperatures, the ethanol evaporated and the residue partitioned between dilute hydrochloric acid and ethyl acetate. The ethyl acetate layer was dried magnesium sulphate and evaporated to give l 3 fluoro 4 hydroxyphenyl propane I , 2 diol as an oil which was used in the next stage without purification.iii 1 3 Fluoro 4 hydroxyphenyl propan 2 one A mixture of l 3 fluoro 4 hydroxyphenyl propane 1,2 diol 38g and p toluene sulphonic acid lg in benzene 150ml was heated under reflux with azeotropic removal of water using a Dean and Stark head for 2 hours. The solvent was removed by evaporation and the residue partitioned between water and dichloromethane. The organic layer was washed with sodium bicarbonate solution, dried magnesium sulphate and concentrated to give an oil which was purified by column chromatography on silica gel. 1 3 F luoro 4 hydroxyphenyl propan 2 one was isolated as a low melting crystalline solid. t CDCl3 7.75 3H,S 6.3 2H,S 6.15 lH,S 2.8 3.2 3H,m DESCRIPTION 7 l r3 Fluoro 4 carbomethoxymethoxyphenel1propan 2 one EMI66.1 A mixture of t3 fluoro 4 hydroxyphenyl propan 2 one l0.0g , methyl bromoacetate l0.0g , potassium carbonate lO.Og in acetone 200ml was heated under reflux, with stirring, for three hours, cooled, filtered and evaporated to dryness to give l 3 Fluoro 4carbomethoxymethoxyphenyl propan 2 one which was used without further purification.1H nmr CDC13 7.8 3H,S , 6.35 2H,S , 6.15 3H,S , 5,3 2H,S , 2.8 3.25 3H, complex The above ketone was converted to its ethylene ketal with ethylene glycol in benzene under reflux using a catalytic quantity of p toluenesulphonic acid, in the usual manner. H nmr 27 CDC13 8.7 3H,S , 7.15 2H,S , 6.0 6.4 7H,S on 5.3 2H,S , 2.8 3.3 3H, complex DESCRIPTION 8 1 3 Fluoro 4 2 hydroxvethoxy phenyl 1 propan 2 one ethylene ketalEMI67.1 1 3 Fluoro 4 2 hydroxethoxy phenyl propan 2 one ethylene ketal was prepared using l 3 fiuoro 4 carbornethoxy methoxyphenyl propan 2 one ethylene ketal by an analogous procedure to that described in Description 1.1H nmr 2 CDc13 8.70 3H,s , 7.15 3H, broad s , 5.7 6.35 8H, complex , 2.8 3.2 3him . DESCRIPTION 9 l t3 Fluoro 4 2 hydroxYethoxy Phenyl1 propan 2 one ethylene ketal p toluene sulphonic acid esterEMI68.1 1 3 Fluoro 4 2 hydroxyethoxy phenyl J propan 2 one ethylene ketal p toluene sulphonic acid ester, m.p. 0 79 80 ethanol was prepared from p toluenesulphonyl chloride 4,2g and 1 3 fluoro 4 2 hydroxy ethoxy phenyl3 propan 2 one ethylene ketal 5.Og by an analogous procedure to that described in Description 2. H nmr CDCl 8.85 3H,s 7.65 3H,s , 7.3 2H,s 3 6.2 6.5 4H,m , 5.7 6.l 4H,m , 3.0 3.5 3H, complex , 2.7 2H,d , 2.2 2H,d . DESCRIPTION 10 l F3 Fluoro 4 2 methelaminoethoxy phenyl1propan 2 one EMI69.1 1 3 Fluoro 4 2 methylaminoethoxy phenyl propan 2 one was prepared from l 3 fluoro 4 2 hydroxyethoxy phenyl propan 2 one ethylene ketal p toluenesulphonate ester by an analogous procedure to that described in Description 3.Tile Gi formed was used without further purification. DESCRIPTION 11 1 4 2 Benzylaminoethoxy phenyl propan 2 oneEMI70.1 A mixture of benzylamine 4.91g and 1 4 2 hydroxy ethoxy phenyl propan 2 one ethylene ketal p toluene sulphonate ester 17.24g was heated at 6O C in dimethyl sulphoxide for 6h. The reaction mixture was poured into ice water, the solution extracted with ether, the ether layers washed with water and dried. Evaporation of the solvent gave the title compound as its ethylene ketal 13.6g . Deketalisation of 5g of this material with methanol 2M hydrochloric acid under normal conditions gave 1 4 2 benzylaminoethoxy phenyl propan 2 one, 4.6g . Hnmr CDCl3 7.9 3H,s , 7.0 2H,t , 6.4 2H,s , 6.2 2H,s , 5.95 2H, t 1H , 3.2 2H,d , 2.9 2H,d , 2.7 5H,s . DESCRIPTION 12 1 4 2 1 Piperidine ethoxy phenylZpropan 2 oneEMI71.1 This material was prepared in an identical manner to that described in Description 3 using piperidine instead of methylamine. Hnmr CDC13 8.1 8.7 6H,m , 7.95 3H,s , 7.4 7.7 4H,m , 7.3 2H,t , 6.45 2H,s , 6.0 2H,t , 3.2 2H,d , 2.9 2H,d . DESCRIPTION 13I 4 2 1 omopiperidine ethoxy phenyl propan 2 oneEMI72.1 This material was prepared in an identical manner to that described in Description 3 using homopiperidine instead of methylamine. Hnmr CDCl3 8.1 8.5 8H,m , 7.9 3H,s , 6.8 7.4 6H,m , 6.4 2H,s , 6.0 2H,t , 3.2 2H,d , 2.9 2H,d . DESCRIPTION 14 1 4 2 Ethoxycarbonylaminoethoxy phenyl propan 2 one EMI73.1 Ethyl chloroformate 4.4g was added to a solution of 1 4 2 aminoethoxy phenyllpropan 2 one, ethylene ketal 8.0g in pyridine at 0 C and the solution left at this temperature for 1h. Water was added, followed by 2M hydrochloric acid until the solution was acidic and then extracted with dichloromethane. The organic layers were washed with 2M hydrochloric acid, dried, and evaporated to give the title compound as the ethylene ketal 7.01g .This was deketalised with methanol 2M hydrochloric acid at room temperature to give the title compound 4.13g . Hnmr CDC13 8.85 3Ht , 7.9 3H,s , 6.4 2H,s , 6.4 2K,t , 5.7 6.2 4H,m , 4.7 1H, broad , 3.2 2H,d , 2.9 2H,d . DESCRIPTION 15 1 4 2 Aminoethoxy phenylpropan 2 one, ethylene ketalEMI74.1 Anhydrous ammonia was passed through a solution of 1 4 2 hydroxyethoxy phenyl propan 2 one, ethylene ketal, ptoluene sulphonic ester 1.86g in dimethylsulphoxide 30 ml for 2h at room temperature. The mixture was stirred for 15h at 50 C, cooled and water 50ml was added. The solution was extracted with ether, the organic extracts dried and evaporated to give the title compound. Hnmr CDC13 8.8 3H,s , 8.3 2H, broad, disappears with D20 , 7.2 2H,s , 6.95 2H,t , 5.7 6.3 6H,m , 3.3 2H,d , 2.9 2H, d . DESCRIPTION 16 1 4 2 Methylaminocarbonylaminoethoxy phenyl propan 2 one EMI75.1 A solution of 1 4 2 Aminoethoxy phenyl propan 2 one, ethylene ketal 3.5g was heated under reflux in toluene 20ml containing phosgene for 2h. The solvent was evaporated, benzene added and evaporated. The residue was taken up in dry tetrahydrofuran and methylamine passed through the solution for 0.5h. The solvent was evaporated, the residue taken up in chloroform and washed with 2M hydrochloric acid. The organic layer was dried and evaporated to give the title compound as its ethylene ketal 3.35g . Deketalisation was accomplished with methanol 2M hydrochloric acid at room temperature. Hnmr CDCl3 7.8 3H,s , 7.25 3H,d , 6.35 2H,s 2H,m , 6.0 2H,t , 4.75 1H,m , 4.5 1H,m , 3.2 2H,d , 2.85 2H,d . DESCRIPTION 17I 4 2 Acetylaminoethoxy phenyll propan 2 oneEMI76.1 This material was prepared in a similar manner to that described in Description 14, using acetyl chloride instead of ethyl chloroformate. Hnmr Q, CDCl3 3.05 3H,s , 7.9 3H,s , 6.45 2H,s , 5.8 6.4 4H, complex , 3.25 2H,d , 2.95 2H,d . DESCRIPTION 18 N t2 4 2 Methylaminocarbonylmethoxy phenyl 1 methyl ethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamineEMI77.1 Aqueous methylamine 80ml of a 25 30 solution was added in 4 portions to a solution of N 2 4 2 methoxycarbonyl methoxy phenyl 1 methylethyl 2 hydroxy 2 3 trifluoro methylphenyl ethanamine in methanol at reflux. The solution was heated under reflux for 2.5h, cooled to room temperature, a further 50ml of methylamine solution added and the solution was allowed to stand at ambient temperature 16h. The solution was evaporated to half volume, brine was added and the solution was extracted with dichloromethane. The extracts were washed with brine, dried and evaporated to give the title compound, mp 75 0 80 C. Hnmr CDCl 8.95 3H,d , 6.9 7.7 10H complex , 5.6 2H,s , 5.35 1H, m , 3.35 lah, broad, disappears with D20 ,3.2 2H,d , 2.95 2H,d , 2.45 4H, complex .Passage of hydrogen bromide through a solution of the title compound in ethyl acetate ether for 5 min at OOC precipitated a solid which after two recrystallizations from methanol ethyl acetate gave the RR,SS diastereoisomer, as the hydrobromide salt, mp 199 2000C. The original mother liquor was treated with saturated sodium bicarbonate solution, dried, and evaporated.Trituration with hexane followed by two recrystallizations of the resulting solid from ether hexane gave the RS,SR diastereoisomer, mp 83 850C. DESCRIPTION 19 1 4 2 1 Pyrrolidine ethoxy phenyl propan 2 oneEMI79.1 This material was prepared in an identical manner to that described in Description 3 using pyrrolidine instead of methyl amine Hnmr tCDCl3 8.2 4H,m , 7.85 3H,s , 7.5 4H,m , 7.15 2H,t , 6.35 2H,s , 5.9 2H,t , 3.2 2H,d , 2.9 2H,d . DESCRIPTION 20 N 2 4 2 Ethylaminocarbonylmethoxy phenylF1 methylethyl 2 hydroxy 2 3 trifluoromethylphenyl ethanamineEMI80.1 This material was prepared in an identical manner to that described in Example 5 using 2 hydroxy 2 3 trifluoromethylphenyl ethanamine and 1 4 ethylaminocarbonylmeth oxy phenyl propan 2 one. Hnmr t DMSO d6 9.1 3H,d , 8.95 3H,t , 8.0 1H, broad , 7.7 7.0 5H,m , 6.85 2H,m , 5.55 2H,s , 5.3 1H,t 4.5 1H,broad , 3.15 2H,d , 2.9 2H,d , 2.5 2.2 4H,m , 1.9 1H,m . DESCRPITION 21 N 2 4 Carbomethoxymethoxyphenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine hydrobromide RR,SS diastereoisomerEMI81.1 HBr RR,SS diastereoisomerN 2 4 Carbomethoxymethoxyphenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethaamine 4.0g 58 42 mixture of diastereoisomers was suspended in diethylether 100ml and sufficient methanol added to obtain solution. Hydrogen bromide was passed through the solution for 15 minutes at 0 50C. The top ethereal layer was decanted from the lower oily layer and ethyl acetate 50ml added. After stirring for 30 minutes at 0 C the solid formed was removed by filtration to give the title compound, mp 13780C, of analytical purity and 96 diastereoisomeric purity. Hnmr Z DMSO d6 8.9 3H,s , 6.5 7.4 5H,complex , 6.3 3H,s , 5.25 2H,s , 4.95 1H,q , 3.75 1H,exchanges with D20 , 3.1 2H,d , 2.8 2H,d , 2.5 4H,m , 1.2 2H, exchanges with D20 . DESCRIPTION 22N 2 3 Carbomethoxymethoxyphenyl 1 methylethyl 2 hydroxy 2 3 chlorophenyl ethanamine EMI82.1 The title compound, mp 62 80C was prepared, as a mixture of diastereoisomers of analytical purity, from 2 hydroxy 2 3 chlorophenyl ethanamine 3.71g and l 3 carbomethoxy methoxyphenyl propan 2 one 4.80g by an analogous procedure to that described in Example 1. Hnmr Z CDCl3 8.95 3H,d , 6.95 7.7 7H,complex 2H exchange with D20 , 6.25 3H,s , 5.3 5.6 3H, s on m , 3.1 3.4 3H, complex 2.55 2.95 5H, complex . DESCRIPTION 23 1 4 2 1 Morpholine ethoxy phenyllproPan 2 oneEMI83.1 This material was prepared in an identical manner to that described in Description 3 using morpholine instead of methylamineb Hnmr t CDC13 7.9 3H,s , 7.65 7.2 4H,m , 7.2 2H,t , 6.4 2H,s , 6.3 2H,t , 6.1 5.7 4H,t , 3.15 2H,d , 2.8 2H,d . DESCRIPTION 24 1 4 2 Benzylaminopropoxy phenyl propan 2 one EMI84.1 A mixture of 4 hydroxyphenylpropanone, ethylene ketal 7.0g , chloroacetone 3.32g and potassium carbonate 16.lg was heated under reflux for 16h in acetone containing a trace of potassium iodide. The solution was evaporated, the residue partitioned between ether and water, the layers separated and the ether layer dried magnesium sulphate . Filtration and removal of the solvent gave an oil 8.4g . This was not purified further but heated under reflux for 4h with benzylamine 3.6g in benzene under Dean and Stark conditions. The solvent was evaporated, the residue dissolved in methanol and sodium borohydride 2.6g added portionwise.The methanol was evaporated, the residue partitioned between ether and water, the layers separated and the ether layer dried.Removal of the solvent gave an oil which was dissolved in acetone 2M hydrochloric acid and the solution left at room temperature for 48h. The acetone was evaporated, 2M sodium hydroxide solution added and the mixture extracted with ether, and the ether layers dried. Removal of the solvent gave the title compound as an oil 7.4g . Hnmr CDCl3 8.8 3H,d , 7.9 3H,s , 7.4 1H, broad , 6.9 1H,m , 6.4 2H,s , 6.2 lH,s 2H,d , 3.2 2H,d ,2.9 2H,d ,2.7 5H,m . DESCRIPTION 25 l 2 4 CyanomethoxY phenYg propan 2 oneEMI85.1 Chloroacetonitrile 4.0g was added to a solution of 4 hydroxyphenyl propan 2 one, ethylene ketal 9.7g in acetone loom containing potassium iodide 5.0g and potassium carbonate 7.0g . The mixture was boiled under reflux with stirring for 8 hours. The mixture was cooled, filtered and the solvent evaporated. The residue was dissolved in ether, washed with dilute sodium hydroxide solution, brine, dried magnesium sulphate filtered and evaporated. The residual oil was taken up in methanol 2M hydrochloric acid and allowed to stand at ambient temperature for 2 hours. Water was added, the solution extracted with ether and the combined organic layers dried magnesium sulphate .Evaporation of the solvent gave 1 4 cyanomethoxy phenyg propan 2 one. 1H nmr t CDCl3 7.85 3H,s 6.35 2H,s 5.30 2H,s 3.10 2H,d 2.80 2H,d . DESCRIPTION 26 2 14 Cyanomethoxy phenyl ethanol, 4 toluene sulphonateEMI86.1 A mixture of 4 hydroxyphenethylalcohol 5.0g , chloroacetonitrile 2.7g and potassium carbonate 10.0g was heated under reflux for 24h in acetone containing a trace of potassium iodide. The mixture was filtered, the acetone evaporated and the residue partitioned between chloroform and water. The chloroform layer was washed with 2M sodium hydroxide and dried magnesium sulphate . Filtration and evaporation of the solvent gave 2 4 cyanomethoxy phenyllethanol 7...3go. This was dissolved in dry pyridine, cooled to oOC and a solution of 4 toluene sulphonyl chloride added dropwise. The solution was allowed to stand at ambient temperature for 16h then poured into water and extracted with ether. The ether layers were combined, washed with water, 2M hydrochloric acid, water and dried magnesium sulphate .Filtration and evaporation of the solvent gave the title compound as an oil 8.24g . Hnmr y CDCl3 7.5 3H,s , 7.1 2H,t , 5.75 2H,t , 5.3 2H,s , 3.1 2H, d , 2.8 2H,d , 2.65 2H,d , 2.28 2H,d . DESCRIPTION 27 4 4 2 Dimethylaminoethoxy phenyl 2 methylbutan 2 amine EMI87.1 A mixture of 2 methyl 4 4 hydroxyphenyl butan 2 ol 18.0 g , 2 dimethylaminoethylchloride hydrochloride 14.4g and potassium carbonate 54g was stirred and heated under reflux for 4 days in acetone containing potassium iodide 16.2g . The mixture was filtered, the acetone evaporated and the residue was taken up into chloroform.This was extracted with 2M hydrochloric acid and the chloroform discarded. The acid layer was made basic with 2M sodium hydroxide, extracted with chloroform and the organic layers dried. Filtration and evaporation of the solvent gave 4 4 dimethylaminoethoxy phenyl 2 methyl butan 2 ol as a clear oil 4.01g .Sodium cyanide 0.6g was added to glacial acetic acid 4ml kept at ca 2OOC. To this mixture was added dropwise a cooled solution of concentrated sulphuric acid 2ml in glacial acetic acid 2ml , the temperature being kept to 200C with an ice bath. The ice bath was removed and a solution of the above alcohol 3.5g in glacial acetic acid was added dropwise. The reaction mixture was allowed to attain ambient temperature and then allowed to stand at ambient temperature for 16h. Nitrogen was bubbled through the solution for 0.5h, the mixture poured into water, neutralized with solid sodium carbonate, ex tracted with ethyl acetate, dried and evaporated to give the title compound as its N formyl derivative 2.8g . This was heated under reflux in sodium hydroxide solution 20 w w for 24h, the solution cooled, extracted with chloroform, dried and evaporated to give the title compound as an oil 2.08g . Hnmr CDCl3 8.9 6H,s , 8.45 2H,m , 8.3 2H,m , 7.7 6H,s , 7.55 2H, broad , 7.35 2H,t , 6.0 2H,t , 3.2 2H,d , 2.9 2H,d . DESCRIPTION 28 1 4 2 Diethylaminoethoxy phenyl propan 2 oneEMI89.1 This was prepared in an identical manner to the compound described in Description 3 using diethylamine instead of methylamine. Hnmr CDCl3 8.5 6H,t , 7.9 3H,s , 7.5 4H,q , 7.2 2H,t , 6.4 2H, s , 6.0 2H,t , 3.1 2H,d , 2.9 2H,d . Demonstration of Effectiveness of Compounds I Anti hyperglycaemic activity Female CFLP mice, each weighing approximately 25 g, were fasted for 24 hours prior to the study.The compounds under study were administered orally as an aqueous solution to each of 6 mice. 6 mice were given water as a control. 30 minutes later a blood sample 20 pl was obtained from the tail for the analysis of blood glucose. Immediately after taking this blood sample, glucose 1 g kg body weight was administered subcutaneously to each mouse. Blood samples were then obtained from each mouse at 30 minute intervals for 120 minutes. Compounds that produced a significant P 0.05 reduction of blood glucose, compared with control mice given water, at any time interval, were considered active. The area under the blood glucose curve over the 2 hour period after the adninistration of the glucose was calculated for each compound and compared with the value for control animals. EMI91.1 tb Compound SEP of SEP Dose SEP Reduction SEP in SEP area SEP under tb Example SEP No SEP SEP moles kg SEP po SEP Blood SEP glucose SEP curve SEP tb SEP Control SEP O SEP tb SEP 1 SEP 1 SEP 33 tb SEP 2 SEP 5 SEP 49 tb SEP 3 SEP 1 SEP 56 tb SEP 4 SEP 2.5 SEP 18 tb SEP 5 SEP 1 SEP 38 tb SEP 50 SEP 333.5 SEP tb SEP 7 SEP 1 SEP 33 tb SEP 8 SEP 1 SEP 51 tb SEP 9 SEP 1 SEP 39 tb SEP 10 SEP 1 SEP 30 tb SEP 11 SEP 1 SEP 64 tb SEP 13 SEP 1 SEP 62 tb SEP 14 SEP 1 SEP 68 tb SEP 15 SEP 1 SEP 17 tb SEP 16 SEP 1 SEP 68 tb SEP 18 SEP 2.5 SEP 50 tb SEP 19 SEP 1 SEP 46 tb SEP 20 SEP 2.5 SEP 36 tb SEP 21 SEP 2.5 SEP 44 tb SEP 22 SEP 1 SEP 43 tb SEP 23 SEP 2.5 SEP 20 tb SEP 24 SEP 1 SEP 47 tb SEP 28 SEP 0.5 SEP 42 tb SEP 29 SEP 12.5 SEP 48 tb SEP 31 SEP 50 SEP 45 tb SEP 35 SEP 250 SEP 18 tb SEP 36 SEP 50 SEP 56 tb SEP 38 SEP 0.5 SEP 63 tb II Effect on energy expenditure The effect of the compounds on the energy expenditure of mice was demonstrated by means of the following procedure. Female CFLP mice each weighing approximately 24 g, were given food and water ad lib before and during the experiment. The compounds were dissolved in water by addition of one mole of hydrochloric acid per mole of compound and these solutions were acministered orally to each of 12 mice. A further 12 mice were dosed orally with water. The mice were placed in boxes through which air was drawn and the oxygen content of the air leaving the boxes was measured. The energy expenditure of the mice was calculated for 21 hours after dosing from the volume of air leaving the boxes and its oxygen content following the principles described by J B de V Weir,J Physiol London 109, 1 9, 1949 . The food intake of the mice was measured over this same period of 21 hours.The results are express as a percentage of the mean food intake or rate of energy expenditure of the mice dosed with water. EMI93.1 tb Compound SEP of SEP Dose SEP Mean SEP Energy SEP Mean SEP Food tb Example SEP No. SEP mg kg SEP po SEP Expenditure SEP SEP Intake SEP SEP SEP tb SEP Control SEP SEP 100 SEP 100 tb SEP 1 SEP 26.1 SEP 129 SEP 98 tb SEP la SEP 2.61 SEP 120 SEP 94 tb SEP 2 SEP 26.9 SEP 127 SEP SEP 98 tb SEP 3 SEP 25.6 SEP 125 SEP 83 tb SEP 4 SEP 24.6 SEP 110 SEP 76 tb SEP 5 SEP 30.2 SEP 134 SEP 102 tb SEP 6 SEP 28.9 SEP 97 SEP 98 tb SEP 7 SEP 28.3 SEP 125 SEP 109 tb SEP 8 SEP 31.6 SEP 135 SEP 97 tb SEP 9 SEP 28.3 SEP 129 SEP 109 tb SEP 10 SEP 27.3 SEP 118 SEP 89 tb SEP 11 SEP 25.3 SEP 148 SEP 1 SEP 79 tb SEP 12 SEP SEP 24.2 SEP 120 SEP 99 tb SEP 13 SEP 29.5 SEP 139 SEP 78 tb SEP 14 SEP 1 SEP 23.9 SEP 141 SEP 111 tb SEP 15 SEP 26.9 SEP 117 SEP 77 tb SEP 16 SEP 23.4 SEP 141 SEP 91 tb SEP 17 SEP 22.0 SEP 114 SEP 87 tb SEP 18 SEP 26.3 SEP 131 SEP 80 tb SEP 19 SEP 27.3 SEP 135 SEP 94 tb SEP 20 SEP 25.3 SEP 115 SEP 86 tb SEP 21 SEP 23.6 SEP 119 SEP 102 tb SEP 22 SEP 24.3 SEP 124 SEP 84 tb SEP 23 SEP 6.5 SEP 109 SEP 112 tb SEP 24 SEP 6.6 SEP 139 SEP 102 tb SEP 25 SEP 25.5 SEP 117 SEP 87 tb SEP 26 SEP 26.4 SEP 125 SEP 63 tb SEP 27 SEP 24.2 SEP 143 SEP 100 tb SEP 28 SEP 21.8 SEP 135 SEP 108 tb SEP 29 SEP 21.8 SEP 123 SEP 107 tb SEP 30 SEP 22.6 SEP 125 SEP 95 tb EMI94.1 tb Compound SEP of SEP Dose SEP Mean SEP Energy SEP Mean SEP Food tb Example SEP No. SEP mg kg SEP po SEP Expenditure SEP SEP Intake SEP tb SEP 31 SEP 24.3 SEP 100 SEP 59 tb SEP 33 SEP 26.3 SEP 131 SEP 80 tb SEP 34 SEP 18.4 SEP 117 SEP 103 tb SEP 35 SEP 23.1 SEP 95 SEP 83 tb SEP 36 SEP 22.7 SEP 132 SEP 78 tb SEP 38 SEP 19.2 SEP 132 SEP 81 tb III Cardiac activity Rat hearts were perfused by the Langendorff procedure as follows Hearts were dissected free within 30 seconds of death and reverse perfused via the aorta and coronary vessels with Krebs Ringer bicarbonate solution pH 7.4, 370C gassed with 95 oxygen 5 carbon 3 dioxide at a flow rate between 8 12 cm minute. Responses were observed after injection of drug dissolved in isotonic saline into the perfusion media.Heart rate and tension were displayed on an OrmedMX2P recorder via a tension transducer and heart ratemeter. Results are expressed as a percentage of the maximum response due to salbutamol. EMI96.1 tb Compound SEP of SEP Dose SEP added SEP Heart SEP Heart tb Example SEP No SEP to SEP perfusate SEP g SEP Tension SEP Rate tb Salbutamol SEP 100 SEP 100 tb SEP 1 SEP 10 SEP 7 SEP 0 tb SEP 2 SEP 10 SEP 0 SEP 0 tb SEP 3 SEP 10 SEP 4 SEP 38 tb SEP 7 SEP 10 SEP 18 SEP 73 tb SEP 8 SEP 10 SEP 20 SEP 73 tb SEP 9 SEP 10 SEP 53 SEP 73 tb SEP 10 SEP 10 SEP 33 SEP 14 tb SEP 11 SEP 10 SEP 60 SEP 45 tb SEP 14 SEP 30 SEP 0 SEP 0 tb SEP 18 SEP 30 SEP 7 SEP 12 tb SEP 20 SEP 30 SEP 0 SEP 12 tb SEP 21 SEP 30 SEP 24 SEP 22 tb SEP 22 SEP 30 SEP 22 SEP 57 tb IV. ANTI OBESITY ACTIVITY The compounds were administered by oral gavage in water or carboxymethyl cellulose suspension to genetically obese mice daily for 28 days.At the end of the time the carcass composition was determined. The results obtained were as follows COMPOUND OF DOSE g LIPID MOUSEEXAMPLE NO. mg kg p.o. TREATED CONTROL la 13.1 12.54 19.13 8 15.8 17.91 19.89 14 3.61 19.83 22.90 V. PLATELET AGGREGATION INHIBITION ACTIVITY Collagen induced platelet aggregation in human whole blood in vitro. Collagen added to stirred citrated blood causes platelet aggregation. As the platelets aggregate, the concentration of single platelets falls. Hence the aggregation response can be quantified as a per cent fall in single platelet count. Inhibitors of aggregation, such as aspirin and dipyridamole, reduce the response to collagen V. PLATELET AGGREGATION INHIBITION ACTIVITY Cont Blood drawn from volunteers who denied taking aspirin within the previous seven days was mixed withO.1 vol 129 mM trisodium citrate, dispensed into 0.5 ml aliquots and kept at 250. Collagen Hormon Chemie,Munich or 154 mM NaCl control was added to each aliquot of blood stirred at 1100 rpm in an aggregometer at 37 after 3 mins pre incubation with compound or appropriate solvent.Aggregates were fixed by addition of 0.5 vol 4.5 formaldehyde or 0.05 vol phosphatebuffered glutaraldehyde. Single platelets were counted electronically. Responses, expressed as per cent fall in platelet count, were obtained to a range of collagen concentrations. The concentration producing 50 maximal effect EC50 was estimated from log1O concentrationresponse curves. Dose ratios were calculated by dividing the EC50 obtained in the presence of compound under test by the control EC50. Results are summarised in the table.COMPOUND FINAL CONCENTRATION IN DOSE RATIO WHOLE BLOOD UM . Aspirin 200 2.4 0.3 3 Dipyridamole 200 3.7 1.1 4 Example 24 100 5.9Example 8 100 4.8 VI. ANTI INFLAMMATORY ACTIVITY The method used is based on that described byG. Tonelli et al Endocrinology, 77, 625 634, 1965 . An inflammation is induced iS the rat ear by the application of 50 p1 of a 1 solution of croton oil in tetrahydrofuran, test compounds being dissolved in the irritant vehicle. After 6 hours the inflammation is assessed by killing the animals and weighing the ears. Topical anti inflammatory activity of a compound is generally considered to be shown when a significant 5 level reduction in ear weight is seen compared to nondrug treated control.EMI99.1 COMPOUND SEP OF SEP DOSE SEP ACTIVITY tb EXAMPLE SEP NO. SEP mg rat SEP ear tb 24 SEP 1.35 SEP Active tb Toxicity No toxicity was observed during the above experiments.